Ginkgo Bioworks Holdings Inc vs Roivant Sciences Ltd. Common Shares — how do they compare? Ginkgo Bioworks Holdings Inc trades at $11.57 (market cap $772.39M), while Roivant Sciences Ltd. Common Shares trades at $34.21 (market cap $25.09B). The key difference: Roivant Sciences Ltd. Common Shares is far larger — about 32.5× Ginkgo Bioworks Holdings Inc's market cap, and Roivant Sciences Ltd. Common Shares is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Roivant Sciences Ltd. Common Shares for 0 Days on average.
| DNA | ROIV | |
|---|---|---|
Market Cap | $772.39M | $25.09B |
Volume | 6,453,273 | 5,738,571 |
Sector | Health | Health |
52-Week High | $15.83 | $41.81 |
52-Week Low | $5.48 | $16.04 |
Typical Hold Time | 7 Days | 0 Days |
Enterprise Value | $874.34M | $21.36B |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $11.47, down 7.57% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported a net loss of $312.76 million on $170.16 million revenue in 2025, with a high gross margin of 68.04% but negative net income margin. Recent news includes a $17.5 million ARPA-H subcontract for RNA medicine manufacturing, highlighting growth initiatives amid financial challenges.
The outlook remains speculative with significant cash burn and persistent losses, though partnerships and government contracts offer potential catalysts. Risks include high operating costs and reliance on funding, while analyst sentiment is divided equally between buy, hold, and sell ratings. Investment hinges on the company's ability to monetize its technology and achieve profitability.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →Roivant Sciences develops medicines by building and supporting biotechnology subsidiaries, known as Vants. Its programs span areas such as immunology, neuroscience, and rare diseases.
Read more on ROIV →